{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:36:52Z","timestamp":1794958612804,"version":"4.9.1"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Metastatic pancreatic ductal adenocarcinoma (PDAC) continues to carry a poor prognosis despite advances in treatment, underscoring the need for simple and accessible biomarkers that reflect tumor\u2013host interactions. The Global Immune\u2013Nutrition\u2013Inflammation Index (GINI), which combines inflammatory, immune, and nutritional parameters, may offer improved prognostic stratification compared with conventional indices. Materials and Methods: This retrospective cohort study included 126 patients with metastatic PDAC treated between 2015 and 2024. GINI, neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were calculated using baseline laboratory data. Discriminative ability was evaluated by receiver operating characteristic (ROC) analysis. Survival outcomes were assessed using Kaplan\u2013Meier curves and Cox proportional hazards models. Results: Among the evaluated indices, GINI showed the best discriminative performance (AUC, 0.769; 95% CI, 0.637\u20130.900), with a sensitivity of 78.8% and specificity of 76.9%. Patients with lower GINI values had significantly longer overall survival than those with higher values (median OS, 11.0 vs. 7.0 months; p = 0.014). Although progression-free survival differed statistically (p = 0.006), median PFS was the same in both groups (5.0 months). In univariable analysis, higher GINI was associated with worse OS (HR, 1.67; p = 0.022) and PFS (HR, 1.75; p = 0.012). However, in multivariable analysis, ECOG performance status remained the only consistent independent predictor, and GINI was no longer significant. Conclusions: GINI is a practical and biologically meaningful biomarker that improves risk discrimination in metastatic PDAC. While it does not retain independent prognostic significance, its ability to capture the overall tumor\u2013host interaction supports its use as a complementary tool for baseline risk assessment.<\/jats:p>","DOI":"10.3390\/medicina62071279","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:51:25Z","timestamp":1783003885000},"page":"1279","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Global Immune\u2013Nutrition\u2013Inflammation Index Is Associated with Survival Outcomes and Enhances Prognostic Discrimination in Metastatic Pancreatic Cancer"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7721-5646","authenticated-orcid":false,"given":"Kamuran","family":"Y\u00fcceer","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-5234","authenticated-orcid":false,"given":"Oktay","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevl\u00fcde","family":"Inan\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Ozkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri 38039, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hayat, U., Croce, P.S., Saadeh, A., Desai, K., Appiah, J., Khan, S., Khan, Y.I., Kumar, K., and Hanif, A. (2025). Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041129"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"TPS4230","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4230","article-title":"Trial in progress: RASolute 302\u2014A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS (ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Wolpin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.21873\/anticanres.16572","article-title":"Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment","volume":"43","author":"Aoyama","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Emanuel, A., Krampitz, J., Rosenberger, F., Kind, S., and R\u00f6tzer, I. (2022). Nutritional Interventions in Pancreatic Cancer: A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14092212"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101191","DOI":"10.5306\/wjco.v16.i1.101191","article-title":"Prognostic impact of inflammatory and nutritional biomarkers in pancreatic cancer","volume":"16","author":"Teja","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.pan.2025.02.014","article-title":"Inflammatory markers in predicting survival in pancreatic cancer: A Systematic review and Meta-Analysis","volume":"25","author":"Worapongpaiboon","year":"2025","journal-title":"Pancreatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2147\/JIR.S496703","article-title":"The Clinical Value of the Combined Detection of Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Prognostic Nutritional Index (PNI) in Early Diagnosis of Gastric Cancer","volume":"18","author":"Zheng","year":"2025","journal-title":"J. Inflamm. Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"He, K., Si, L., Pan, X., Sun, L., Wang, Y., Lu, J., and Wang, X. (2022). Preoperative Systemic Immune-Inflammation Index (SII) as a Superior Predictor of Long-Term Survival Outcome in Patients with Stage I-II Gastric Cancer After Radical Surgery. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.829689"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Menyhart, O., Fekete, J.T., and Gy\u0151rffy, B. (2024). Inflammation and Colorectal Cancer: A Meta-Analysis of the Prognostic Significance of the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI). Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25158441"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Topkan, E., Selek, U., Pehlivan, B., Kucuk, A., Ozturk, D., Ozdemir, B.S., Besen, A.A., and Mertsoylu, H. (2023). The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. Cancers, 15.","DOI":"10.3390\/cancers15184512"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.21873\/cdp.10353","article-title":"Global Immune-Nutrition-Information Index Is Independent Prognostic Factor for Gastric Cancer Patients Who Received Curative Treatment","volume":"4","author":"Aoyama","year":"2024","journal-title":"Cancer Diagn. Progn."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2147\/IJGM.S516108","article-title":"The Global Immune-Nutrition Inflammation Index for Predicting Coronary Slow Flow Phenomenon in Patients with Angina and No Obstructive Coronary Arteries","volume":"18","author":"Guo","year":"2025","journal-title":"Int. J. Gen. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25525","DOI":"10.1038\/s41598-025-11148-x","article-title":"The prognostic importance of the global immune-nutrition-information index (GINI) in patients with Ras wild type metastatic colorectal cancer","volume":"15","author":"Bozkurt","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.3390\/curroncol31090372","article-title":"Unraveling the Predictive Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) on Survival Outcomes in Patients with Grade 4 Adult-Type Diffuse Gliomas","volume":"31","author":"Aydin","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Feng, Z., Yi, H., Xiao, J., Huang, Z., Tu, Y., and Liu, B. (2025). The global immune-nutrition-inflammation index predicts pathological response and survival in esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1717477"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11605-019-04187-z","article-title":"Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection","volume":"24","author":"Jomrich","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pan.2019.12.010","article-title":"A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer","volume":"20","author":"France","year":"2020","journal-title":"Pancreatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102180","DOI":"10.1016\/j.ctrv.2021.102180","article-title":"Treatment landscape of metastatic pancreatic cancer","volume":"96","author":"Winder","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.21037\/jgo-2025-283","article-title":"Peripheral blood neutrophil-to-lymphocyte ratio as a prognostic marker and its association with the tumor-immune microenvironment in pancreatic cancer: A retrospective cohort study","volume":"16","author":"Li","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Han, R., Tian, Z., Jiang, Y., Guan, G., Wang, X., Sun, X., Yu, Y., and Jing, X. (2022). Prognostic significance of the systemic immune inflammation index in patients with metastatic and unresectable pancreatic cancer. Front. Surg., 9.","DOI":"10.3389\/fsurg.2022.915599"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10238-021-00785-x","article-title":"Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: A meta-analysis","volume":"22","author":"Li","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sun, Y., Liang, M., Wang, X., Dong, W., Wu, Z., Sun, F., Lu, X., Wang, F., Liu, S., and Wang, M. (2025). Inflammatory and nutritional markers predict response and prognosis of patients with locally advanced gastric cancer receiving neoadjuvant immunochemotherapy. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-03874-3"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:25:47Z","timestamp":1783679147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/7\/1279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["medicina62071279"],"URL":"https:\/\/doi.org\/10.3390\/medicina62071279","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}